公开(公告)号：WO2014047493A1

公开(公告)日：2014-03-27

申请号：PCT/US2013/061009

申请日：2013-09-20

Applicant: ABBOTT LABORATORIES

Inventor： WALTON, Joseph ,  BAXTER, Jeffrey ,  MAZER, Terrence ,  ZOCHARSKI, Philip ,  LIPARI, John ,  KENSLER, Ann ,  EDENS, Neile ,  STEPP, Emily ,  DEVITT-MAICHER, Amy ,  WOLF, David ,  MUSTAD, Vikkie

IPC: A23L1/30 ,  A61K9/00 ,  A61K31/19

CPC classification number: A61K9/107 ,  A23L33/10 ,  A23L33/40 ,  A23V2002/00 ,  A23V2200/00 ,  A23V2200/302 ,  A23V2200/316 ,  A23V2250/30

Abstract: Disclosed are nutritional compositions, and methods of using and making the nutritional compositions, that include calcium beta-hydroxy-beta-methylbutyrate and protein. The calcium beta-hydroxy-beta-methylbutyrate is in sequestered or ion-exchanged form to reduce the interaction of the calcium with the protein in the nutritional composition and improve the overall stability of the nutritional composition.

Abstract translation: 公开了营养组合物，以及使用和制备营养组合物的方法，其包括β-羟基-β-甲基丁酸钙和蛋白质。 β-羟基-β-甲基丁酸钙是螯合或离子交换形式，以减少营养组合物中钙与蛋白质的相互作用，并提高营养组合物的整体稳定性。

公开(公告)号：WO2003089440A1

公开(公告)日：2003-10-30

申请号：PCT/US2003/011997

申请日：2003-04-17

Applicant: ABBOTT LABORATORIES

Inventor： CANNON, John, B. ,  HANSRANI, Pawan ,  HERTZLER, Russell, L. ,  LIPARI, John ,  SANZGIRI, Yeshwant, D. ,  WITTENBERGER, Steven, J.

IPC: C07D498/18

CPC classification number: C07D498/18

Abstract: Two new crystalline polymorphs of the compound of formula (I) and methods for their use and preparation are disclosed.

Abstract translation: 公开了式（I）化合物的两种新的结晶多晶型物及其使用和制备方法。

公开(公告)号：WO1998022106A1

公开(公告)日：1998-05-28

申请号：PCT/US1997020794

申请日：1997-11-12

Applicant: ABBOTT LABORATORIES

Inventor： ABBOTT LABORATORIES ,  LIPARI, John ,  AL-RAZZAK, Laman, A. ,  GHOSH, Soumojeet ,  GAO, Rong ,  KAUL, Dilip

IPC: A61K31/425

CPC classification number: A61K38/55 ,  A61K9/4858 ,  A61K31/341 ,  A61K31/426 ,  A61K31/4433 ,  A61K31/47 ,  A61K31/4704 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/513 ,  A61K31/5375 ,  A61K31/551 ,  A61K38/05 ,  A61K47/10 ,  A61K47/12 ,  A61K47/26 ,  A61K47/44 ,  Y02A50/465

Abstract: A liquid pharmaceutical composition providing improved oral bioavailability is disclosed for compounds which are inhibitors of HIV protease. In particular, the composition comprises a solution in a pharmaceutically acceptable organic solvent of (a) the HIV protease inhibitor and optionally, (b) a surfactant. The composition can optionally be encapsulated in either hard gelating capsules or soft elastic capsules (SEC).

Abstract translation: 对于作为HIV蛋白酶抑制剂的化合物，公开了提供改善的口服生物利用度的液体药物组合物。 特别地，组合物包含（a）HIV蛋白酶抑制剂和任选的（b）表面活性剂的药学上可接受的有机溶剂中的溶液。 组合物可任选地包封在硬胶囊或软弹性胶囊（SEC）中。

公开(公告)号：EP0942721A1

公开(公告)日：1999-09-22

申请号：EP97947510.0

申请日：1997-11-12

Applicant: Abbott Laboratories

Inventor： LIPARI, John ,  AL-RAZZAK, Laman, A. ,  GHOSH, Soumojeet ,  GAO, Rong ,  KAUL, Dilip

IPC: A61K31 ,  A61K9 ,  A61K38 ,  A61K45 ,  A61K47 ,  A61P31 ,  A61P43

CPC classification number: A61K38/55 ,  A61K9/4858 ,  A61K31/341 ,  A61K31/426 ,  A61K31/4433 ,  A61K31/47 ,  A61K31/4704 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/513 ,  A61K31/5375 ,  A61K31/551 ,  A61K38/05 ,  A61K47/10 ,  A61K47/12 ,  A61K47/26 ,  A61K47/44 ,  Y02A50/465

Abstract: A liquid pharmaceutical composition providing improved oral bioavailability is disclosed for compounds which are inhibitors of HIV protease. In particular, the composition comprises a solution in a pharmaceutically acceptable organic solvent of (a) the HIV protease inhibitor and optionally, (b) a surfactant. The composition can optionally be encapsulated in either hard gelatin capsules or soft elastic capsules (SEC).

Abstract translation: 公开了作为HIV蛋白酶抑制剂的化合物提供改善的口服生物利用度的液体药物组合物。 特别地，组合物包含在（a）HIV蛋白酶抑制剂和任选的（b）表面活性剂的药学上可接受的有机溶剂中的溶液。 该组合物可以任选地包封在硬凝胶胶囊或软弹性胶囊（SEC）中。

公开(公告)号：EP1497297A1

公开(公告)日：2005-01-19

申请号：EP03721755.1

申请日：2003-04-17

Applicant: Abbott Laboratories

Inventor： CANNON, John, B. ,  HANSRANI, Pawan ,  HERTZLER, Russell, L. ,  LIPARI, John ,  SANZGIRI, Yeshwant, D. ,  WITTENBERGER, Steven, J.

IPC: C07D498/18 ,  A61K31/439 ,  A61P37/06

CPC classification number: C07D498/18

Abstract: Two new crystalline polymorphs of the compound of formula (I) and methods for their use and preparation are disclosed.

公开(公告)号：EP0942721B1

公开(公告)日：2003-01-22

申请号：EP97947510.0

申请日：1997-11-12

Applicant: Abbott Laboratories

Inventor： LIPARI, John ,  AL-RAZZAK, Laman, A. ,  GHOSH, Soumojeet ,  GAO, Rong ,  KAUL, Dilip

IPC: A61K31/425 ,  A61K31/535 ,  A61K31/55 ,  A61K47/10 ,  A61K47/12 ,  A61K9/48

CPC classification number: A61K38/55 ,  A61K9/4858 ,  A61K31/341 ,  A61K31/426 ,  A61K31/4433 ,  A61K31/47 ,  A61K31/4704 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/513 ,  A61K31/5375 ,  A61K31/551 ,  A61K38/05 ,  A61K47/10 ,  A61K47/12 ,  A61K47/26 ,  A61K47/44 ,  Y02A50/465

Abstract: A liquid pharmaceutical composition providing improved oral bioavailability is disclosed for compounds which are inhibitors of HIV protease. In particular, the composition comprises a solution in a pharmaceutically acceptable organic solvent of (a) the HIV protease inhibitor and optionally, (b) a surfactant. The composition can optionally be encapsulated in either hard gelatin capsules or soft elastic capsules (SEC).